Form 4: Reviva Pharmaceuticals Director Acquires 8,200 Stock Options

Richard A. Margolin, a director at Reviva Pharmaceuticals, was granted 8,200 stock options on December 10, 2024, which will vest after one year.

Summary

• Richard A. Margolin, a director of Reviva Pharmaceuticals Holdings, Inc., was granted 8,200 stock options on December 10, 2024.
• The options have an exercise price of $2.52 per share.
• The options will vest 100% on the one-year anniversary of the grant date, provided Mr. Margolin remains a director.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting period encourages continued service and commitment from the director.

Industry Context

Stock option grants to directors are a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting period of one year is relatively common, designed to retain directors and align their interests with the long-term success of the company.
• The exercise price is set at the closing price of the common stock on the grant date, which is a typical practice to ensure the options have value.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, equity, Reviva Pharmaceuticals, insider trading, beneficial ownership